Provided by Tiger Trade Technology Pte. Ltd.

Alto Neuroscience Inc

36.25
+1.975.75%
Post-market: 36.500.2500+0.69%19:30 EDT
Volume:867.97K
Turnover:30.76M
Market Cap:1.41B
PE:-15.22
High:36.99
Open:33.96
Low:33.52
Close:34.28
52wk High:36.99
52wk Low:3.41
Shares:38.87M
Float Shares:29.65M
Volume Ratio:1.94
T/O Rate:2.93%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.3816
EPS(LYR):-2.1918
ROE:-49.17%
ROA:-26.79%
PB:6.43
PE(LYR):-16.54

Loading ...

Alto Neuroscience announces ALTO-101 did not achieve statistical significance

TIPRANKS
·
Apr 02

Alto Neuroscience Shares Down 18.8% at $19.01 in Extended Trade After Schizophrenia Cognition Study Misses Primary Endpoint

THOMSON REUTERS
·
Apr 02

Alto Neuroscience says Phase 2 ALTO-101 schizophrenia cognition study misses primary endpoint

Reuters
·
Apr 02

Alto Neuroscience Inc: Development of Alto-207 Remains Top Priority for Company; Phase 2B on Track to Initiate in 1H 2026

THOMSON REUTERS
·
Apr 02

Alto Neuroscience Inc: in Proof-of-Concept Study, Alto-101 Did Not Achieve Statistical Significance on Primary Endpoint

THOMSON REUTERS
·
Apr 02

Alto Neuroscience:Developed Modified-Release, Once-Daily Oral Formulation of Alto-101,Plans to Explore Partnering Opportunities for This Formulation

THOMSON REUTERS
·
Apr 02

Alto Neuroscience announces virtual annual meeting; record-date shares outstanding total 31.9 million

Reuters
·
Mar 27

Alto Neuroscience Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Mar 21

Analysts Offer Insights on Healthcare Companies: Alto Neuroscience, Inc. (ANRO), Johnson & Johnson (JNJ) and InspireMD (NSPR)

TIPRANKS
·
Mar 19

Alto Neuroscience Inc expected to post a loss of 52 cents a share - Earnings Preview

Reuters
·
Mar 19

Alto Neuroscience Is Maintained at Outperform by Baird

Dow Jones
·
Mar 18

U.S. RESEARCH ROUNDUP-Factset, Lensar, Starbucks

Reuters
·
Mar 18

Alto Neuroscience Inc : Baird Raises Target Price to $41 From $22

THOMSON REUTERS
·
Mar 18

Alto Neuroscience: Advancing Late-Stage CNS Pipeline and Strengthened Balance Sheet Support Favorable Risk-Reward Profile

TIPRANKS
·
Mar 18

Alto Neuroscience Is Maintained at Neutral by Wedbush

Dow Jones
·
Mar 17

Alto Neuroscience price target raised to $22 from $13 at Wedbush

TIPRANKS
·
Mar 17

Alto Neuroscience Inc : Wedbush Raises Target Price to $22 From $13

THOMSON REUTERS
·
Mar 17

Alto Neuroscience: Advancing Precision-Psychiatry Pipeline and De-Risked Trials Support Buy Rating

TIPRANKS
·
Mar 17

Wedbush Raises Alto Neuroscience Price Target to $22 From $13, Maintains Neutral Rating

MT Newswires Live
·
Mar 17

Alto Neuroscience Inc. releases corporate presentation on its biomarker-driven CNS drug pipeline with five mid-to-late-stage data readouts

Reuters
·
Mar 16